Bone safety with risedronate: histomorphometric studies at different dose levels and exposure

@article{Recker2014BoneSW,
  title={Bone safety with risedronate: histomorphometric studies at different dose levels and exposure},
  author={Robert Roy Recker and L.-G. Ste-Marie and Pascale M. Chavassieux and Michael R Mcclung and Mark Walden Lundy},
  journal={Osteoporosis International},
  year={2014},
  volume={26},
  pages={327-337}
}
This report describes bone safety and histomorphometric data across different dose levels and dosing frequencies of risedronate. Normal bone structure and histomorphometric data were observed, with ongoing bone remodeling and mineralization regardless of dose. These data are reassuring and do not suggest compromised bone remodeling during treatment with established risedronate regimens. The efficacy and bone safety of risedronate 5 mg daily were established in pivotal phase III randomized… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 6 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Comparison between 150 mg monthly and 5 mg daily risedronate in postmenopausal osteoporosis; effects on bone quality and bone remodelling [abstract P485

  • P Chavassieux, N Portero, +5 authors R Recker
  • Bone 44(Suppl
  • 2009
Highly Influential
4 Excerpts

Prescribing information, revised July 2013. http://pi.amgen.com/united_states/prolia/prolia_pi.pdf

  • Prolia® denosumab
  • Accessed 26 Nov 2013 Osteoporos Int
  • 2015
1 Excerpt

Bone safety of a novel delayed-release risedronate 35 mg once-a-week assessed by bone histology and histomorphometry [abstract SU0421

  • R Recker, I Valter, +8 authors M McClung
  • J Bone Miner Res
  • 2011
2 Excerpts

Similar Papers

Loading similar papers…